LP
DNTH icon

LMR Partners’s Dianthus Therapeutics DNTH Stock Holding History

LMR Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Buy
223,995
+107,551
+92% +$9.39M 0.08% 219
2026
Q1 		$9.77M Buy
+116,444
New +$6.74M 0.02% 444
2024
Q2 		– Sell
-7,478
Closed -$224K – 1148
2024
Q1 		$224K Buy
+7,478
New +$163K ﹤0.01% 853
2022
Q4 		– Sell
-667
Closed -$15K – 1151
2022
Q3 		$15K Hold
667
– – ﹤0.01% 1176
2022
Q2 		$13K Buy
+667
New +$16.5K ﹤0.01% 1249

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

LMR Partners's DNTH Position: Q2 2026 in Review

LMR Partners increased its Dianthus Therapeutics (DNTH) stake by 92% in Q2 2026, buying an estimated $9.39M and bringing the position to 223,995 shares worth $21.8M. The position accounts for 0.08% of the portfolio, ranked #219.

LMR Partners first reported a position in DNTH in Q2 2022 and has held it in 5 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • LMR Partners held 223,995 shares of Dianthus Therapeutics worth $21.8M as of Q2 2026.
  • LMR Partners bought 107,551 Dianthus Therapeutics shares in Q2 2026, an estimated $9.39M.
  • Dianthus Therapeutics made up 0.08% of LMR Partners's portfolio in Q2 2026, its #219 holding.
  • LMR Partners first reported a position in Dianthus Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.